Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIIa randomized double-blind active-controlled study of an MDCK cell-derived quadrivalent split influenza vaccine in people aged 3 years and older
CTR20254267Phase 3Active
- Sponsor
- Xinnuoming Biotech
- Start
- Oct 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of quadrivalent influenza vaccine (split virion), inactivated (MDCK cell) in influenza, sponsored by Xinnuoming Biotech. Started Oct 2025; status: active.
02
Drugs
quadrivalent influenza vaccine (split virion), inactivated (MDCK cell)
03
Conditions
influenza
Beyond the preview
Go deeper on CTR20254267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254267.